1. 138 Phase 1 dose-escalation study of STRO-002, an anti-folate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced platinum-resistant/refractory epithelial ovarian cancer (OC). (13th November 2020) Authors: Naumann, R; Braiteh, F; Diaz, J; Hamilton, E; Diab, S; Schilder, R; Moroney, J; Martin, L; Uyar, D; O'Malley, D; Penson, R; DiLea, C; Palumbo, M; DeAlmeida, V; Berman, C; Matheny, S; Molina, A Journal: International journal of gynecological cancer Issue: Volume 30(2020)Supplement 3 Page Start: A61 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 311PEarly results from an open-label phase 1b/II study of eribulin mesylate (EM) + pegvorhyaluronidase alfa (PEGHP20) combination for the treatment of patients with HER2-negative, high-hyaluronan (HA) metastatic breast cancer (MBC). (23rd October 2018) Authors: Shum, M; Assikis, V J; Savulsky, C; Zhu, W; Iyer, P; Xing, D; Berman, C; Lokker, N A; Alvarez, R H Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 789TiPHALO 109-301: Phase III, randomized, double-blind, placebo-controlled study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients with previously untreated hyaluronan (HA)-high stage IV pancreatic ductal adenocarcinoma (PDA). (23rd October 2018) Authors: Van Cutsem, E; Corrie, P G; Ducreux, M P; Sigal, D; Sahai, V; Oh, D-Y; Bullock, A; Bang, Y-J; Baron, A D; Hendifar, A; Li, C-P; Philip, P; Reni, M; Zalupski, M; Zheng, L; Berman, C; Chondros, D; Tempero, M A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P-225Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial. (2nd July 2019) Authors: Javle, M; Borbath, I; Clarke, S; Hitre, E; Louvet, C; Macarulla, T; Oh, D; Spratlin, J; Valle, J; Weiss, K; Berman, C; Howland, M; Ye, Y; Cho, T; Moran, S; Abou-Alfa, G Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗